FDA seeks Provenge Phase III enrollment suspension

Dendreon (DNDN) said it was asked by FDA to suspend patient enrollment in a second Phase III trial (D9902) of DNDN's Provenge vaccine to treat hormone resistant prostate cancer. The suspension relates...